Global New Drug Progress Showdown: Hengrui Retains Top Spot, CSPC, Hansoh, and Sinopharm Among Top 10

Jun 30, 2025 07:45 CST Updated 07:45

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Sino Biopharm

Pharmaceutical R&D Developer

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

CSPC

Developer of finished drugs and active pharmaceutical ingredients

Insight The database shows,2025 In the first half of the year, nearly1200 The progress of a new drug has changed. Among them,59 A new drug has successfully garnered regulatory approval for the first time, entering the commercialization phase; additionally, there are...52 Submitted the listing application, exceeding100 A New Drug Successfully Enters Clinical TrialsIIIPhase.(Data statistics as of June 29, for specific details see the caption below)

From the perspective of research and development institutions,Hengrui Pharma relies on42 The Absolute Number of New Drugs Advancing Takes the Lead, Ranking First, continuing to lead in leaps and bounds.Pfizer, AstraZeneca, Novartis, CSPCCSPC followed closely, ranking in the top five. Notably, this is the first time CSPC has made it into...TOP5 Array.

Apart from Hengrui Pharma and CSPC,In ChinaThe top ten pharmaceutical companies also includeHansoh Pharma and Sino Biopharm。

Overall, the number of new drugs that made progress in the first half of this year exceeded10 Payment is available.14 Domestic pharmaceutical companies, only Chinese pharmaceutical companies have4 Home, the rest are multinational pharmaceutical giants.

Data Description: Including subsidiaries, sourced from the Dingxiangyuan Insight Database Global New Drug module. Filters include "Global Highest Progress" ≥ Phase I clinical trials (including those with unknown phases), "Project Active Status" as active, global highest status time from 2024.1.1 to 2024.12.31, new drug type as new drugs (excluding improved new drugs and biosimilars, hereinafter the same), and development organizations as enterprises (excluding universities, hospitals, and research institutions) (data manually verified and organized; please point out any errors). Early-stage clinical = Phase I + Phase I/II, late-stage clinical = Phase II, Phase II/III, Phase III, regulatory submission = approved for marketing + applied for marketing.

This article will briefly review the highlights of new drug development from the four Chinese companies on the list, for readers' reference only.

Hengrui: Growth Curve Reaches Turning Point

From Continuous BD Overseas Deals to a Successful IPO on the Hong Kong Stock Exchange, Hengrui Pharma Enters a New Stage of DevelopmentEarnings Report Shows Hengrui Pharma's 2024 Revenue at 27.985 Billion Yuan（+22.6%）Net profit attributable to shareholders was 6.337 billion yuan, a significant increase of 47.3%, includingThe core growth engine is innovative drugs.。

According to statistics, the proportion of Hengrui Pharma's innovative drug revenue in total revenue has increased from 38.1% in 2022 to46.3% in 2024This is mainly due to its continuous increase in R&D investment. In 2024, Hengrui Pharma's R&D investment reached a new high of 8.2 billion yuan.

Source: Insight compilation

Hengrui Pharma has ranked first in the global new drug progress list for many consecutive years. In the first half of this year, Hengrui had over 40 new drugs with progress updates, far surpassing the second place.(Pfizer, 20 New Drugs Undergo Changes), among which 5 new drugs were approved for the first time, as follows:

January 2025, Recasiranib(PCSK9 monoclonal antibody)Approved for single-agent use inAdult patients with non-familial hypercholesterolemia and mixed dyslipidemia, or in combination with statins, etc.Primary Hypercholesterolemia andAdult patients with mixed dyslipidemia.
March 2025, Emma Xitinib(JAK1 Inhibitor)Approved for ankylosing spondylitis. The indications were then expanded to include rheumatoid arthritis and atopic dermatitis within one month.
May 2025, Ruikang Trastuzumab（HER2 ADC）Approved for second-line non-small cell lung cancer.
May 2025,Fosaprepitant Palonosetron(Compound preparation)Approved for the treatment of acute or delayed nausea and vomiting caused by chemotherapy.
May 2025, Famitinib(Multi-target Tyrosine Kinase Inhibitor)Approved for use in combination with Camrelizumab as a second-line treatment for cervical cancer.

In terms of pharmaceutical deals, Hengrui Pharma has also achieved fruitful results, successively licensing the oral lipoprotein(a) inhibitor HRS-5346 and the oral GnRH receptor antagonist SHR7280 to Merck & Co. and Merck KGaA, respectively.

CSPC: Accelerating Innovation and Transformation

In the first half of this year, CSPC's innovation process has significantly accelerated, with a total ofProgress of 14 New Drugs Has Changed，Indications cover diabetes, obesity, depression, cardiovascular diseases, autoimmune diseases, cancer, etc. Among these new drugs, one has been approved for the first time, and two have successfully entered phase III clinical trials.

January 2025, Pluogliptin(DPP4 Inhibitor)Approved for improving blood glucose control in adult patients with type 2 diabetes.
January 2025，Amoxapine（SNRIs）Launch Phase III Clinical Trials for Treating Patients with Depression.
2025April,SYHX1901(Multi-target Tyrosine Kinase Inhibitor)Initiate TreatmentPhase III Clinical Trial for Patients with Moderate to Severe Plaque Psoriasis.

Overall, CSPC currentlyThere are more than 200 innovative drug and innovative formulation projects under development. According to the news release from CSPC,It is expected that by the end of 2028,The company will have more than 50 new drugs or new indications submitted for marketing.。

In terms of international expansion, CSPC has reached three deals this year.Total Amount Reaches Up to 7.635 Billion US Dollars, the down payment is also $140 million.

Source: Insight Database

Hansoh Pharma: Outward Licensing Becomes Normalized

Hansoh Pharma's innovative drug revenue has increased from 4.4 billion yuan in 2021 to 9.5 billion yuan in 2024, accounting for a growing proportion of total revenue.From 45% to 77%, is expected to further improve in 25 years,Breakthrough 10 Billion YuanThe main driving factors are the continuous increase in innovative product sales and the rapid growth in licensing revenue.

According to statistics, Hansoh Pharma currently has 9 innovative drugs approved for marketing, including 6 self-developed products and 3 licensed products. Analysts predict that revenue from Aumolertinib alone could reach 6 billion yuan by 2025.

Source: Insight Compilation

Hansoh Pharma's Outward Licensing Currently AlsoHas entered a routine stateChemical PhaseIn June this year, Hansoh PharmaGLP-1/GIPHansoh Pharma Grants Regeneron Global Rights (excluding China) for the Development, Manufacturing, and Commercialization of Dual Receptor Agonist HS-20094, with a Total Amount Up to $2.01 Billion, Including an Upfront Payment of $80 Million. These Licensing Revenues Will Become an Important Component of Hansoh's Revenue.

Source: Insight Database

TodayIn the first half of the year, Hansoh Pharma had a total ofProgress of 13 New Drugs Has Changed, including the BTK inhibitor introduced from Lupeng PharmaLobutinib has been submitted for marketing approval in May. IL-23 monoclonal antibody introduced from Qybio.QX004N Initiated Phase III Clinical Trial for Plaque Psoriasis, B7-H4 AD Licensed to GSKC HS-20089 has also progressed to Phase III clinical trials.

As these products continue to advance, they are expected to bring new performance increments to Hansoh Pharma.

Sino Biopharm: A Surge of Innovative Drugs on the Horizon

In the first half of this year, Sino BiopharmProgress of 12 New Drugs Has Changed, among which onlyHER2 Inhibitor ZongletinibIt was introduced from Boehringer Ingelheim, all others areSelf-developed Products。

In terms of progress,Zongeitinib has already filed for NDA in January this year, and its market launch is imminent. Additionally, SYK inhibitors TQB3473 in MarchLaunched Phase III Clinical Trials for Immune Thrombocytopenia, with 6 New Entries into Clinical Trials.Among them BCG009 is the first ophthalmic new drug developed by Sino Biopharm., which received its first IND approval in May this year.

Source: Insight Compilation

The annual report shows,ChinaSino BiopharmSeventeen Innovative Products Have Been Launched，In the future, every year there will beAbout 5 Innovative Products Approved，It is expected to exceed 30 by 2027, and the revenue share of innovative products will also increase from 42% in 2024.Increase to 60%。

Moreover, according to public information, out-licensing has been regarded as one of the most important strategic goals by Sino Biopharm. Currently,The companyFor multiple innovative assets with global commercialization potential,Have initiated in-depth negotiations with multiple multinational pharmaceutical companies and leading biotech firms., and hasA landmark heavyweight outbound licensing deal is set to land in the near future.This will further drive the performance growth of Sino Biopharm.